Wed, Nov 26, 2014, 2:08 PM EST - U.S. Markets close in 1 hr 52 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jun 4, 2013 6:49 PM Flag

    OT: ficltuzumab

    $$$$
    It might be prudent to pay attention to the AVEO re-structuring conference call tomorrow AM. They are expected to announce development plans for ficla, a MAB of the HGF/c-Met pathway. Whatever strategy they employ, it'll be interesting to see how they intend to dance with Cabo as an obvious competitor in the c-Met space. They are currently fully enrolled in a P2 in NSCLC comparing gefitinib plus ficla to gefitinib monotherapy. Early results have been favorable, for all the same rationale that supports Cabo.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      For those following the progress of other modalities of cMET inhibition.
      The following posted in the JCO May 28th, 2013...

      "Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib"
      GLTA

 
EXEL
1.749+0.029(+1.69%)2:08 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.